Skip to main content
. 2026 Jun 6;16:17537. doi: 10.1038/s41598-026-55860-8

Table 5.

Histopathological changes among different Schistosoma mansoni-infected mice groups, treated with praziquantel and dapagliflozin as mono- or combined therapy.

Histopathological changes Score Mice groups a P-value
Infected non-treated (n = 6) *** DMSO (n = 5) *** PZQ (n = 6) DAPA (n = 5) *, *** DAPA + PZQ (n = 6) *, **, ***
Lobular inflammation None P = 0.001
Mild
Moderate 2 (33.33%) 4 (80%) 5 (83.33%)
Marked 6 (100%) 5 (100%) 4 (66.67%) 1 (20%) 1 (16.67%)
Focal necrosis None
Minimal -
Mild
Moderate 2 (33.33%) 4 (80%) 5 (83.33%)
Marked 6 (100%) 5 (100%) 4 (66.67%) 1 (20%) 1 (16.67%)
Portal tract inflammation and expansion None P ≤ 0.001
Mild 1 (16.67%)
Moderate 1 (16.67%) 5 (100%) 5 (83.33%)
Marked 6 (100%) 5 (100%) 4 (66.66%) 1 (16.67%)
Hydropic degeneration None 6 (100%) 5 (100%) 5 (100%) 6 (100%) P ≤ 0.001
Minimal 1 (16.67%)
Mild
Moderate 2 (33.33%)
Marked 3 (50%)
Inflammatory cellular infiltrate Minimal P = 0.003
Mild 2 (33.33%)
Moderate 2 (33.33%) 4 (80%) 3 (50%)
Marked 6 (100%) 5 (100%) 4 (66.67%) 1 (20%) 1 (16.67%)

a Monte Carlo test. Data are expressed as number and percent

DAPA: dapagliflozin; DMSO: dimethyl sulfoxide; PZQ: praziquantel

* Significant difference against infected non-treated, and DMSO-treated groups at P˂ 0.05 (lobular inflammation, focal necrosis, portal tract inflammation and expansion, inflammatory cellular infiltrate)

** Significant difference against PZQ-treated group at P˂ 0.01 (inflammatory cellular infiltrate)

*** Significant difference against PZQ-treated group at P˂ 0.01 (hydropic degeneration)